Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial

Citation:
Imam Waked, Gamal Shiha, Roula Qaqish B., Gamal Esmat, Mohamed Hassany Ayman Yosry, Mohammad Mohey A. Reham Soliman, Naglaa Allam, Tarik Asselah Naglaa Zayed, Rebecca Redman Coleen Hall, and Wahid Doss Niloufar Mobashery. "Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial." The Lancet Gastroenterology and Hepatology 111, no. 1 (2016): 36-44.